40 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Concise SAR Exploration Based on the"Head-to-Tail" Approach: Discovery of PI4KIIIa Inhibitors Bearing Diverse Scaffolds.
Japan Tobacco
Design and synthesis of novel and potent allosteric HIV-1 integrase inhibitors with a spirocyclic moiety.
Japan Tobacco
Design and synthesis of novel fluorene derivatives as inhibitors of pyruvate dehydrogenase kinase.
Japan Tobacco
Discovery and SAR of JTE-151: A Novel RORγ Inhibitor for Clinical Development.
Japan Tobacco
Optimization Efforts for Identification of Novel Highly Potent Keap1-Nrf2 Protein-Protein Interaction Inhibitors.
Japan Tobacco
Discovery of Novel NLRP3 Inflammasome Inhibitors Composed of an Oxazole Scaffold Bearing an Acylsulfamide.
Japan Tobacco
Methyl and Fluorine Effects in Novel Orally Bioavailable Keap1-Nrf2 PPI Inhibitor.
Japan Tobacco
The discovery of 3,3-dimethyl-1,2,3,4-tetrahydroquinoxaline-1-carboxamides as AMPD2 inhibitors with a novel mechanism of action.
Japan Tobacco
Fragment-based lead discovery to identify novel inhibitors that target the ATP binding site of pyruvate dehydrogenase kinases.
Japan Tobacco
Orally bioavailable HCV NS5A inhibitors of unsymmetrical structural class.
Japan Tobacco
Discovery of Selective Transforming Growth Factor β Type II Receptor Inhibitors as Antifibrosis Agents.
Japan Tobacco
Discovery of a Janus Kinase Inhibitor Bearing a Highly Three-Dimensional Spiro Scaffold: JTE-052 (Delgocitinib) as a New Dermatological Agent to Treat Inflammatory Skin Disorders.
Japan Tobacco
Discovery of a novel unsymmetrical structural class of HCV NS5A inhibitors with low picomolar antiviral activity.
Japan Tobacco
Symmetry-based ligand design and evaluation of small molecule inhibitors of programmed cell death-1/programmed death-ligand 1 interaction.
Japan Tobacco
Optimization of an azetidine series as inhibitors of colony stimulating factor-1 receptor (CSF-1R) Type II to lead to the clinical candidate JTE-952.
Japan Tobacco
Optimization of oxadiazole derivatives with a spirocyclic cyclohexane structure as novel GPR119 agonists.
Japan Tobacco
Lead generation and optimization of novel GPR119 agonists with a spirocyclic cyclohexane structure.
Japan Tobacco
Discovery of potent liver-selective stearoyl-CoA desaturase-1 (SCD1) inhibitors, thiazole-4-acetic acid derivatives, for the treatment of diabetes, hepatic steatosis, and obesity.
Japan Tobacco
Design and synthesis of novel and potent GPR119 agonists with a spirocyclic structure.
Japan Tobacco
Discovery of JTZ-951: A HIF Prolyl Hydroxylase Inhibitor for the Treatment of Renal Anemia.
Japan Tobacco
Human dihydroorotate dehydrogenase (hDHODH) inhibitors and their use in targeting oncological diseases sensitive to pyrimidine starvation
Drug Discovery And Clinic
NOVEL COMPOUND EXHIBITING THERAPEUTIC EFFECT ON INFLAMMATORY DISEASE AS P38 MAP KINASE INHIBITOR
Prazertherapeutics
INHIBITORS AND DEGRADERS OF JANUS KINASE 2
H. Lee Moffitt Cancer Center and Research Institute
3-TETRAZOLYLMETHYL-1,3,5-TRIAZIN-2,4-DIONE COMPOUND INHIBITING CORONAVIRUS 3CL PROTEASE ACTIVITY AND PREPARATION METHOD AND USE THEREOF
Shaanxi Panlong Pharmaceutical Co.
Combination treatments comprising administration of 1H-pyrazolo[4,3-b]pyridines
H. Lundbeck
Pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them
Les Laboratoires Servier
Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation.
Cedars-Sinai Research Institute
Receptor occupancy and adenylate cyclase activation in AR 4-2J rat pancreatic acinar cell membranes by analogs of pituitary adenylate cyclase-activating peptides amino-terminally shortened or modified at position 1, 2, 3, 20, or 21.
Universit&Acute
Discovery and characterization of 2-anilino-4- (thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agents.
Cyclacel
Stable benzotriazole esters as mechanism-based inactivators of the severe acute respiratory syndrome 3CL protease.
Academia Sinica